-
Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
•
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully launched its initial public offering (IPO) on the Hong Kong Stock Exchange. The offering price ranges from HKD68.44 to HKD75.28 per share, with net proceeds potentially reaching HKD603.3 million (USD77.6 million) if calculated at the…
-
Ascendis Pharma’s TransCon hGH sBLA for Adult GHD Accepted by FDA
•
Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for TransCon hGH (lonapegsomatropin-tcgd) for the treatment of adult growth hormone deficiency (GHD). The FDA’s decision is anticipated by the Prescription Drug User Fee…
-
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
•
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement with compatriot firm Ascendis Pharma A/S (NASDAQ: ASND), a specialist in rare diseases. The collaboration grants Novo Nordisk exclusive rights to utilize Ascendis’ TransCon technology platform globally for the development, manufacturing, and commercialization of proprietary…
-
Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap
•
This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma A/S (NASDAQ: ASND), a Denmark-based pharmaceutical company specializing in rare diseases, for its hypoparathyroidism treatment, palopegteriparatide. The therapy, to be marketed as Yorvipath, is a once-daily prodrug of parathyroid hormone (PTH[1-34]) designed to address the…
-
Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA
•
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has announced that the National Medical Products Administration (NMPA) has accepted for review a marketing approval filing for its lonapegsomatropin, TransCon hGH, a once-weekly long-acting growth hormone. This drug, which is the first long-acting…
-
WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into a partnership agreement with Visen Pharmaceuticals, a joint venture between Denmark’s Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital. Under the terms of the deal, Visen Pharmaceuticals will entrust WuXi Biologics…
-
Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia
•
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to…
-
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
•
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. Morgan Stanley and Jefferies are acting as co-sponsors. The proceeds will be used to support research and development (R&D)…
